Univariate analysis of clinically significant liver injury in individuals with FA who received HSCT
| Variable . | PLI∗ (n = 21) . | No PLI (n = 29) . | P value . |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 12 (57.1) | 19 (65.5) | .76 |
| Male | 9 (42.9) | 10 (34.5) | |
| Race, n (%) | |||
| Caucasian | 17 (81) | 23 (79.3) | .42 |
| African American | 3 (14.3) | 4 (13.8) | |
| Hispanic | 0 | 2 (6.9) | |
| Asian | 1 (4.8) | 0 | |
| Age (y) at HSCT, median (IQR) | 6.7 (5.5-10.3) | 10.1 (6.3-12.8) | .05 |
| Complementation group, n (%) | |||
| FANCA | 5 (29.4) | 12 (54.5) | .21 |
| Non-FANCA | 12 (70.6) | 10 (45.5) | |
| Androgen use, n (%) | |||
| Yes | 7 (33.3) | 6 (20.7) | .50 |
| No | 14 (66.7) | 23 (79.3) | |
| Donor type, n (%) | |||
| Related | 2 (9.5) | 9 (28.1) | .20 |
| Unrelated | 19 (90.5) | 23 (71.9) | |
| Degree of match, n (%) | |||
| Fully matched | 12 (57.1) | 16 (55.2) | .82 |
| Mismatched | In year 9 (42.9) | 13 (44.8) | |
| Donor source, n (%) | |||
| Bone marrow | 2 (9.5) | 5 (17.2) | .19 |
| PBSC | 17 (81) | 24 (82.8) | |
| Cord | 2 (9.5) | 0 | |
| TBI in conditioning regimen, n (%) | |||
| Yes | 14 (66.7) | 31 (96.9) | .009 |
| No | 7 (33.3) | 1 (3.1) | |
| GVHD prophylaxis, n (%) | |||
| CNI based | 11 (52.4) | 12 (37.5) | .65 |
| TCD | 2 (9.5) | 4 (12.5) | |
| Both CNI and TCD | 8 (38.1) | 15 (46.9) | |
| Other | 0 | 1 (3.1) | |
| Acute GVHD score at day 100, n (%) | |||
| Grades 1-4 | 0 | 2 (6.2) | .67 |
| GVHD with liver involvement, n (%) | 0 | 1 (3.1) | 1.00 |
| TA-TMA, n (%) | 4 (19.0) | 15 (46.9) | .08 |
| Variable . | PLI∗ (n = 21) . | No PLI (n = 29) . | P value . |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 12 (57.1) | 19 (65.5) | .76 |
| Male | 9 (42.9) | 10 (34.5) | |
| Race, n (%) | |||
| Caucasian | 17 (81) | 23 (79.3) | .42 |
| African American | 3 (14.3) | 4 (13.8) | |
| Hispanic | 0 | 2 (6.9) | |
| Asian | 1 (4.8) | 0 | |
| Age (y) at HSCT, median (IQR) | 6.7 (5.5-10.3) | 10.1 (6.3-12.8) | .05 |
| Complementation group, n (%) | |||
| FANCA | 5 (29.4) | 12 (54.5) | .21 |
| Non-FANCA | 12 (70.6) | 10 (45.5) | |
| Androgen use, n (%) | |||
| Yes | 7 (33.3) | 6 (20.7) | .50 |
| No | 14 (66.7) | 23 (79.3) | |
| Donor type, n (%) | |||
| Related | 2 (9.5) | 9 (28.1) | .20 |
| Unrelated | 19 (90.5) | 23 (71.9) | |
| Degree of match, n (%) | |||
| Fully matched | 12 (57.1) | 16 (55.2) | .82 |
| Mismatched | In year 9 (42.9) | 13 (44.8) | |
| Donor source, n (%) | |||
| Bone marrow | 2 (9.5) | 5 (17.2) | .19 |
| PBSC | 17 (81) | 24 (82.8) | |
| Cord | 2 (9.5) | 0 | |
| TBI in conditioning regimen, n (%) | |||
| Yes | 14 (66.7) | 31 (96.9) | .009 |
| No | 7 (33.3) | 1 (3.1) | |
| GVHD prophylaxis, n (%) | |||
| CNI based | 11 (52.4) | 12 (37.5) | .65 |
| TCD | 2 (9.5) | 4 (12.5) | |
| Both CNI and TCD | 8 (38.1) | 15 (46.9) | |
| Other | 0 | 1 (3.1) | |
| Acute GVHD score at day 100, n (%) | |||
| Grades 1-4 | 0 | 2 (6.2) | .67 |
| GVHD with liver involvement, n (%) | 0 | 1 (3.1) | 1.00 |
| TA-TMA, n (%) | 4 (19.0) | 15 (46.9) | .08 |
CNI, calcineurin inhibitor; PBSC, peripheral blood stem cell; TCD, T-cell depletion.
Persistent liver injury.